Literature DB >> 19584160

Regulation of replicative and stress-induced senescence by RSK4, which is down-regulated in human tumors.

Laura López-Vicente1, Gemma Armengol, Berta Pons, Laura Coch, Elisabet Argelaguet, Matilde Lleonart, Javier Hernández-Losa, Inés de Torres, Santiago Ramon y Cajal.   

Abstract

PURPOSE: The control of senescence and its biochemical pathways is a crucial factor for understanding cell transformation. In a large RNA interference screen, the RSK4 gene was found to be related to p53-dependent arrest. The purpose of the present study was to investigate the potential role of RSK4 as a tumor suppressor gene. EXPERIMENTAL
DESIGN: RSK4 expression was determined by quantitative real-time PCR and immunoblot in 30 colon and 20 renal carcinomas, and in 7 colon adenomas. Two HCT116 colon carcinoma cell lines (p53 wt and p53 null), IMR90 human fibroblasts, and E1A-expressing IMR90 cells were infected with RSK4 cDNA and/or shRNA. RSK4 expression levels were analyzed in HCT116 p53 wt or p53 null and IMR90 after senescence induction by quantitative real-time PCR and Western blot.
RESULTS: The RSK4 gene was down-regulated in 27 of 30 colon carcinomas (P < 0.001), 16 of 20 renal cell carcinomas (P < 0.01), and 6 of 7 colon adenomas (P < 0.01). In vitro overexpression of RSK4 induced cell arrest and senescence features in normal fibroblasts and malignant colon carcinoma cell lines. Interestingly, in these cell lines RSK4 mRNA levels were increased both in replicative and stress-induced senescence. Moreover, IMR90 partially immortalized by RSK4 shRNA and HCT116 with this short hairpin RNA were more resistant to cisplatin treatment. Finally, cells expressing E1A or Rb short interfering RNA were resistant to RSK4-mediated senescence.
CONCLUSION: These results support the concept that RSK4 may be an important tumor suppressor gene by modulating senescence induction and contributing to cell proliferation control in colon carcinogenesis and renal cell carcinomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19584160     DOI: 10.1158/1078-0432.CCR-08-3159

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

1.  Frequent epigenetic inactivation of RSK4 by promoter methylation in cancerous and non-cancerous tissues of breast cancer.

Authors:  Qiuyun Li; Yi Jiang; Wei Wei; Yinan Ji; Hui Gao; Jianlun Liu
Journal:  Med Oncol       Date:  2013-12-11       Impact factor: 3.064

2.  Two p90 ribosomal S6 kinase isoforms are involved in the regulation of mitotic and meiotic arrest in Artemia.

Authors:  Ru-Bing Duan; Li Zhang; Dian-Fu Chen; Fan Yang; Jin-Shu Yang; Wei-Jun Yang
Journal:  J Biol Chem       Date:  2014-04-22       Impact factor: 5.157

3.  RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation.

Authors:  Madhurima Saha; Audrey Carriere; Mujeeburahiman Cheerathodi; Xiaocui Zhang; Geneviève Lavoie; John Rush; Philippe P Roux; Bryan A Ballif
Journal:  Biochem J       Date:  2012-10-01       Impact factor: 3.857

Review 4.  Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases.

Authors:  Marie Cargnello; Philippe P Roux
Journal:  Microbiol Mol Biol Rev       Date:  2011-03       Impact factor: 11.056

5.  Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers.

Authors:  Summer B Dewdney; B J Rimel; Premal H Thaker; Dominic M Thompson; Amy Schmidt; Phyllis Huettner; David G Mutch; Feng Gao; Paul J Goodfellow
Journal:  Clin Cancer Res       Date:  2011-03-03       Impact factor: 12.531

Review 6.  Inactivation of X-linked tumor suppressor genes in human cancer.

Authors:  Runhua Liu; Mandy Kain; Lizhong Wang
Journal:  Future Oncol       Date:  2012-04       Impact factor: 3.404

7.  Ribosomal S6 kinase 4 (RSK4) expression in ovarian tumors and its regulation by antineoplastic drugs in ovarian cancer cell lines.

Authors:  Fabian Arechavaleta-Velasco; Moises Zeferino-Toquero; Isaias Estrada-Moscoso; Fazlollah Shahram Imani-Razavi; Aleida Olivares; Carlos Eduardo Perez-Juarez; Laura Diaz-Cueto
Journal:  Med Oncol       Date:  2016-01-05       Impact factor: 3.064

8.  RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

Authors:  Violeta Serra; Pieter J A Eichhorn; Celina García-García; Yasir H Ibrahim; Ludmila Prudkin; Gertrudis Sánchez; Olga Rodríguez; Pilar Antón; Josep-Lluís Parra; Sara Marlow; Maurizio Scaltriti; José Pérez-Garcia; Aleix Prat; Joaquín Arribas; William C Hahn; So Young Kim; José Baselga
Journal:  J Clin Invest       Date:  2013-05-01       Impact factor: 14.808

9.  Low expression of RSK4 predicts poor prognosis in patients with colorectal cancer.

Authors:  Jun Cai; Hong Ma; Fang Huang; Dichao Zhu; Lei Zhao; Yudan Yang; Jianping Bi; Tao Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

10.  Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer.

Authors:  Stelios Chrysostomou; Rajat Roy; Filippo Prischi; Lucksamon Thamlikitkul; Kathryn L Chapman; Uwais Mufti; Robert Peach; Laifeng Ding; David Hancock; Christopher Moore; Miriam Molina-Arcas; Francesco Mauri; David J Pinato; Joel M Abrahams; Silvia Ottaviani; Leandro Castellano; Georgios Giamas; Jennifer Pascoe; Devmini Moonamale; Sarah Pirrie; Claire Gaunt; Lucinda Billingham; Neil M Steven; Michael Cullen; David Hrouda; Mathias Winkler; John Post; Philip Cohen; Seth J Salpeter; Vered Bar; Adi Zundelevich; Shay Golan; Dan Leibovici; Romain Lara; David R Klug; Sophia N Yaliraki; Mauricio Barahona; Yulan Wang; Julian Downward; J Mark Skehel; Maruf M U Ali; Michael J Seckl; Olivier E Pardo
Journal:  Sci Transl Med       Date:  2021-07-14       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.